Stoke Therapeutics, Inc.

STOK

Stoke Therapeutics, Inc.

STOK

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-16Shares Purchased (TTM):0Shares Sold (TTM):343,760

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:66,967,710Shares Outstanding:63,063,507Institutional Ownership Pct.:106.19%

Earnings Market Reaction:

Filing Date:2026-08-03Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	110	156	84	83	101	275	128	150	193	179	191	190
Available For Sale Securities Debt Securities Curr…	183	188	200	165	146	83	89	89	89	-	10	25
Accounts Receivable Net Current	7	4	6	9	-	-	2	-	-	-	-	-
Prepaid Expense Current	15	10	9	8	14	13	11	10	10	11	11	11
Restricted Cash Current	-	0	0	0	0	0	0	0	0	-	-	-
Interest Receivable Current	2	2	2	2	2	1	1	1	0	0	0	0
Other Assets Current	6	7	4	6	7	5	2	4	4	4	3	4
Deferred Costs Current	-	-	-	-	-	-	-	-	-	0	-	-
Assets Current	323	367	306	272	270	376	233	254	297	193	215	230
Available For Sale Securities Debt Securities Nonc…	62	67	106	80	107	23	30	30	-	-	-	-
Restricted Cash Noncurrent	3	3	0	1	1	1	1	0	0	1	1	1
Operating Lease Right Of Use Asset	2	2	3	4	2	4	4	5	5	6	7	3
Property Plant And Equipment Net	5	3	3	3	3	4	4	4	5	5	6	6
Assets	394	443	418	360	385	407	272	293	308	205	228	240
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	5	7	5	6	4	2	2	2	4	2	2	3
Deferred Revenue Current	9	10	12	6	9	18	19	32	26	21	15	9
Liabilities Current	42	41	58	42	39	45	40	50	44	36	31	25
Deferred Revenue Noncurrent	6	7	7	9	10	10	-	8	17	25	33	41
Other Liabilities Noncurrent	1	1	1	2	1	2	2	3	4	4	5	1
Liabilities Noncurrent	6	8	8	10	11	12	2	11	21	29	38	42
Liabilities	48	48	66	52	50	57	43	61	65	65	69	67
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	955	943	850	747	736	728	720	712	697	569	561	548
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	1	0	0	-0	-0	0	-0	-	-0	-0
Retained Earnings Accumulated Deficit	-609	-548	-498	-440	-401	-378	-491	-480	-454	-428	-402	-375
Stockholders Equity	346	395	352	308	335	350	229	232	243	140	160	173
Liabilities And Stockholders Equity	394	443	418	360	385	407	272	293	308	205	228	240
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	62	62	59	55	55	55	54	53	52	46	46	44
Shares Outstanding	62	62	59	55	55	55	54	53	52	46	46	44

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.73%	-2.41%	-10.64%	-	-	-	-	-	-	-	-	-
2025	24.75%	28.56%	44.57%	52.85%	88.91%	122.03%	21.98%	25.97%	16.26%	1.09%	-3.15%	-11.63%
2024	23.17%	13.82%	33.61%	6.13%	-10.72%	-13.13%	-7.20%	-15.25%	-18.62%	-20.86%	5.52%	25.59%
2023	-	-	-	-5.30%	-32.65%	-42.39%	-18.56%	8.45%	1.44%	85.38%	113.85%	150.00%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	7.69	8.99	5.28	6.53	6.98	8.41	5.81	5.09	6.67	5.43	6.99	9.13
Quick Ratio	7.34	8.74	5.13	6.34	6.63	8.12	5.53	4.89	6.44	5.13	6.62	8.69
Working Capital	280.61M	325.88M	247.83M	230.71M	231.29M	331.05M	192.70M	203.75M	252.50M	157.69M	184.52M	204.82M
Leverage & Debt
Debt to Equity	0.14	0.12	0.19	0.17	0.15	0.16	0.19	0.26	0.27	0.46	0.43	0.39
Interest Coverage TTM	-15.98	-12.99	-1.50	2.07	3.05	2.92	-8.02	-9.57	-10.08	-11.58	-11.58	-12.77
Debt Ratio	0.12	0.11	0.16	0.14	0.13	0.14	0.16	0.21	0.21	0.32	0.30	0.28
Efficiency & Turnover
Asset Turnover TTM	0.07	0.08	0.53	0.63	0.58	0.62	0.15	0.06	0.05	0.03	0.04	0.04
Days Sales Outstanding TTM	94.98	50.64	7.52	16.42	-	-	16.65	-	-	-	-	-
Receivables Turnover TTM	3.84	7.21	48.51	22.24	-	-	21.92	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-3.15	-2.69	-0.12	0.69	0.90	0.85	-1.65	-1.87	-1.86	-2.35	-2.38	-2.34
Free Cash Flow Per Share TTM	0.18	-2.34	0.76	-1.35	-1.21	1.20	-1.61	-1.50	-1.45	-1.85	-1.88	-1.91
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-809.69%	-577.46%	-11.16%	13.22%	20.15%	20.03%	-277.31%	-700.66%	-755.71%	-1,510.14%	-1,307.21%	-1,214.98%
Net Profit Margin TTM	-753.60%	-529.20%	-3.73%	19.73%	26.26%	26.33%	-243.42%	-629.89%	-683.35%	-1,383.58%	-1,192.47%	-1,118.04%
Growth Metrics
Net Revenue Growth (1Y)	-86.20%	-83.20%	404.50%	1,128.24%	1,218.91%	2,333.81%	316.34%	81.03%	71.35%	-46.12%	-29.22%	1.23%
Net Income Growth (1Y)	-496.12%	-437.70%	-92.26%	-138.47%	-150.68%	-146.32%	-15.01%	1.99%	-1.33%	9.67%	3.59%	3.54%
EPS Growth (1Y)	-450.14%	-409.85%	-92.94%	-136.98%	-148.43%	-137.02%	-30.77%	-19.87%	-21.81%	0.87%	-8.41%	-7.79%
Valuation Metrics
P/E TTM	-10.39	-12.10	-273.00	33.95	12.62	7.65	-6.69	-6.57	-7.27	-5.75	-2.21	-1.69
P/B TTM	6.25	5.20	5.33	4.47	1.98	1.10	2.60	2.98	3.10	4.45	1.45	1.01
P/S TTM	78.30	64.01	10.19	6.70	3.31	2.02	16.30	41.36	49.71	79.59	26.36	18.86
Market Cap	2.16B	2.05B	1.88B	1.38B	662.32M	384.79M	595.72M	692.43M	753.40M	624.33M	231.41M	174.41M
Enterprise Value	2.05B	1.90B	1.80B	1.29B	560.84M	109.97M	467.73M	542.42M	559.92M	445.75M	39.97M	-15.57M
Calculated Values
Free Cash Flow TTM	11.93M	-147.70M	44.92M	-79.31M	-70.53M	69.20M	-87.05M	-84.70M	-80.62M	-85.74M	-82.68M	-84.59M
Net Debt	-110.00M	-155.66M	-84.22M	-83.39M	-101.47M	-274.82M	-127.98M	-150.02M	-193.48M	-178.58M	-191.44M	-189.98M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-16Sale

Owner: Allan, Jonathan

Title: GENERAL COUNSEL & CORP SEC

Shares: 1,457

Price/Share: $29.95

Value: $43,637.15

Shares Owned: 18,086

Relationship: Officer

Ownership: Direct

2026-06-01Sale

Owner: Ticho, Barry

Title: CHIEF MEDICAL OFFICER

Shares: 1,795

Price/Share: $30.58

Value: $54,891.10

Shares Owned: 34,826

Relationship: Officer

Ownership: Direct

2026-05-01Sale

Owner: Ticho, Barry

Title: CHIEF MEDICAL OFFICER

Shares: 2,243

Price/Share: $32.79

Value: $73,547.97

Shares Owned: 36,621

Relationship: Officer

Ownership: Direct

2026-04-01Sale

Owner: Ticho, Barry

Title: CHIEF MEDICAL OFFICER

Shares: 1,838

Price/Share: $32.66

Value: $60,029.08

Shares Owned: 38,864

Relationship: Officer

Ownership: Direct

2026-03-20Sale

Owner: Allan, Jonathan

Title: GENERAL COUNSEL & CORP SEC

Shares: 9,293

Price/Share: $34.02

Value: $316,147.86

Shares Owned: 19,543

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-16	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	1,457	29.95	$43,637.15	18,086	4
2026-06-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,795	30.58	$54,891.10	34,826	4
2026-05-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,243	32.79	$73,547.97	36,621	4
2026-04-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,838	32.66	$60,029.08	38,864	4
2026-03-20	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	9,293	34.02	$316,147.86	19,543	4
2026-03-19	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,461	29.99	$43,815.39	40,702	4
2026-03-18	Hoitt, Jason	Officer	Chief Patient Officer	Direct	Sale	1,931	31.97	$61,734.07	10,276	4
2026-03-18	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	4,628	31.97	$147,957.16	28,836	4
2026-03-18	Leggett, Thomas	Officer	Chief Financial Officer	Direct	Sale	2,382	31.97	$76,152.54	10,172	4
2026-03-13	Levin, Arthur A	Director	-	Direct	Sale	605	36.80	$22,264.00	4,237	4
2026-03-10	Krainer, Adrian R.	Director	-	Direct	Sale	33,243	39.74	$1,321,076.82	283,302	4
2026-03-10	Tzianabos, Arthur	Director,Officer	Interim Executive Chair	Direct	Sale	4,355	40.00	$174,200.00	31,339	4
2026-03-02	Krainer, Adrian R.	Director	-	Direct	Sale	7,229	39.66	$286,702.14	316,545	4
2025-12-08	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	3,978	32.11	$127,733.58	11,831	4
2025-12-08	Kaye, Edward M. Md	Director	-	Direct	Sale	13,430	32.35	$434,460.50	49,124	4
2025-12-05	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	3,662	31.34	$114,767.08	19,798	4
2025-12-05	Kaye, Edward M. Md	Director	-	Direct	Sale	8,548	31.44	$268,749.12	62,554	4
2025-12-05	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	8,785	31.39	$275,761.15	15,809	4
2025-12-03	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	2,292	30.60	$70,135.20	19,612	4
2025-12-03	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,014	30.60	$61,628.40	15,156	4
2025-12-03	Kaye, Edward M. Md	Director	-	Direct	Sale	1,070	30.60	$32,742.00	51,305	4
2025-11-24	Krainer, Adrian R.	Director	-	Direct	Sale	40,472	29.72	$1,202,827.84	323,774	4
2025-11-14	Krainer, Adrian R.	Director	-	Direct	Sale	40,472	26.98	$1,091,934.56	364,246	4
2025-11-03	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,931	27.03	$160,314.93	7,195	4
2025-10-08	Kaye, Edward M. Md	Director	-	Direct	Sale	25,000	30.00	$750,000.00	49,124	4
2025-10-03	Kaye, Edward M. Md	Director	-	Direct	Sale	42,461	25.09	$1,065,346.49	49,124	4
2025-10-03	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	10,000	25.07	$250,700.00	11,831	4
2025-10-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,343	23.64	$126,308.52	13,126	4
2025-09-03	Kaye, Edward M. Md	Director	-	Direct	Sale	45,996	20.13	$925,899.48	91,585	4
2025-09-03	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	6,345	20.07	$127,344.15	11,831	4
2025-09-02	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,501	19.87	$109,304.87	18,469	4
2025-08-18	Kaye, Edward M. Md	Director	-	Direct	Sale	12,126	18.24	$221,178.24	153,470	4
2025-08-18	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	1,683	18.24	$30,697.92	23,948	4
2025-08-18	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,805	18.24	$51,163.20	23,970	4
2025-08-13	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	13,712	15.00	$205,680.00	19,631	4
2025-08-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	4,504	12.82	$57,741.28	16,775	4
2025-07-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	4,503	11.63	$52,369.89	21,279	4
2025-06-04	Skorpios, Trust, Ezbon In…	TenPercentOwner	-	Indirect	Sale	3,000,000	10.20	$30,600,000.00	3,906,181	4
2025-06-03	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	6,471	10.03	$64,904.13	25,782	4
2025-05-02	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	22,790	10.03	$228,583.70	33,998	4
2025-03-19	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	1,945	8.27	$16,085.15	31,565	4
2025-03-19	Kaye, Edward M. Md	Director	-	Direct	Sale	8,907	8.27	$73,660.89	139,346	4
2025-03-19	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	3,333	8.27	$27,563.91	60,629	4
2024-12-23	Blue, Horizon Enterprise …	TenPercentOwner	-	Indirect	Sale	2,000,000	11.50	$23,000,000.00	6,906,181	4
2024-12-09	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	13,666	13.34	$182,304.44	21,476	4
2024-12-09	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,586	12.99	$33,592.14	44,746	4
2024-12-09	Kaye, Edward M. Md	Director,Officer	CEO	Direct	Sale	6,786	12.99	$88,150.14	61,885	4
2024-12-06	Kaye, Edward M. Md	Director,Officer	CEO	Direct	Sale	6,170	12.78	$78,852.60	68,671	4
2024-12-06	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	9,696	12.78	$123,914.88	35,142	4
2024-12-06	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	13,945	12.78	$178,217.10	47,332	4
2024-12-02	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	12.07	$120,700.00	51,277	4
2024-11-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	12.68	$126,800.00	2,485	4
2024-10-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	12.06	$120,600.00	2,485	4
2024-09-19	Blue, Horizon Enterprise …	TenPercentOwner	-	Indirect	Sale	1,937,500	14.05	$27,221,875.00	8,906,181	4
2024-09-03	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	15.16	$151,600.00	2,485	4
2024-08-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	14.58	$145,800.00	2,485	4
2024-07-02	Nash, Huw M.	Officer	Chief Business Officer	Direct	Sale	2,500	13.50	$33,750.00	0	4
2024-07-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	13.75	$137,500.00	2,485	4
2024-06-03	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	15.50	$155,000.00	2,485	4
2024-05-20	Kaye, Edward M. Md	Director,Officer	CEO	Direct	Sale	42,350	15.72	$665,742.00	27,000	4
2024-05-20	Nash, Huw M.	Officer	COO & CBO	Direct	Sale	50,000	15.39	$769,500.00	0	4
2024-05-20	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	8,599	15.04	$129,328.96	2,598	4
2024-05-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	11.37	$113,700.00	2,485	4
2024-04-17	Blue, Horizon Enterprise …	TenPercentOwner	-	Indirect	Sale	3,600,000	11.60	$41,760,000.00	10,843,681	4
2024-04-01	Nash, Huw M.	Officer	COO & CBO	Direct	Sale	61,329	13.42	$823,035.18	0	4
2024-04-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	9,426	13.23	$124,705.98	2,485	4
2024-03-28	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	5,126	13.50	$69,201.00	2,598	4
2024-03-19	Kaye, Edward M. Md	Director,Officer	CEO	Direct	Sale	11,150	6.10	$68,015.00	69,350	4
2024-03-19	Nash, Huw M.	Officer	COO & CBO	Direct	Sale	4,116	6.10	$25,107.60	11,329	4
2024-03-19	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	4,116	6.10	$25,107.60	11,469	4
2024-03-19	Allan, Jonathan	Officer	GENERAL COUNSEL & CORP SEC	Direct	Sale	2,349	6.10	$14,328.90	7,724	4
2024-03-19	Tulipano, Stephen J	Officer	CFO	Direct	Sale	4,116	6.10	$25,107.60	20,746	4
2024-03-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	7.75	$77,500.00	2,485	4
2024-02-01	Ticho, Barry	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,000	4.80	$48,000.00	6,981	4
2024-01-02	Ticho, Barry	Officer	Chief Medical Officer	Direct	Sale	10,000	5.74	$57,400.00	16,981	4
2023-07-03	Ticho, Barry	Officer	Chief Medical Officer	Direct	Sale	15,000	10.60	$159,000.00	25,895	4
2023-06-21	Allan, Jonathan	Officer	General Counsel & Corp Sec	Direct	Sale	1,948	13.48	$26,259.04	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

106.19%

Inst. Shares: 66,967,710

Shares Outstanding: 63,063,507

2025-12-31

112.17%

Inst. Shares: 66,424,236

Shares Outstanding: 59,219,184

2025-09-30

115.02%

Inst. Shares: 67,413,655

Shares Outstanding: 58,611,677

2025-06-30

111.87%

Inst. Shares: 65,279,622

Shares Outstanding: 58,353,855

2025-03-31

109.30%

Inst. Shares: 63,245,133

Shares Outstanding: 57,862,674

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	66,967,710	63,063,507	106.19%
2025-12-31	66,424,236	59,219,184	112.17%
2025-09-30	67,413,655	58,611,677	115.02%
2025-06-30	65,279,622	58,353,855	111.87%
2025-03-31	63,245,133	57,862,674	109.30%
2024-12-31	57,877,230	54,008,883	107.16%
2024-09-30	58,048,086	56,341,074	103.03%
2024-06-30	61,102,907	55,765,948	109.57%
2024-03-31	53,938,853	46,246,889	116.63%
2023-12-31	41,083,293	43,994,862	93.38%
2023-09-30	43,452,000	44,266,017	98.16%
2023-06-30	45,675,976	44,188,464	103.37%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Stoke Therapeutics, Inc. (STOK) — SEC Financial Statements & Analysis

Stoke Therapeutics, Inc. (STOK) is a pharmaceutical preparations company, incorporated in DE. Stoke Therapeutics, Inc. trades on Nasdaq as: STOK. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Stoke Therapeutics, Inc. reported a -86.20% year-over-year revenue growth, a Debt-to-Equity ratio of 0.14x, a Price-to-Sales (P/S) ratio of 78.30x (TTM), a Price-to-Book (P/B) ratio of 6.25x (TTM), at a market cap of $2.16B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -86.20%
Debt To Equity: 0.14x
P/S TTM: 78.30x
P/B TTM: 6.25x
Market Cap: $2.16B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Stoke Therapeutics, Inc. in?

Stoke Therapeutics, Inc. (STOK) operates in the Pharmaceutical Preparations industry.

What is STOK's market cap?

Stoke Therapeutics, Inc. (STOK) has a market capitalization of $2.16B as of 2026-06-30.

What exchange does STOK trade on?

Stoke Therapeutics, Inc. (STOK) trades on the Nasdaq.

Where is Stoke Therapeutics, Inc. incorporated?

Stoke Therapeutics, Inc. is incorporated in DE.